Arcutis Biotherapeutics, Inc.
NASDAQ:ARQTBiotechnology
-$0.51 today
- Market cap
- $3.49B
- Beta
- 1.52
- P/E (TTM)
- -1400.0
- EPS (TTM)
- -$0.02
Volume 0.84M
Average 1.61M
ARQT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Arcutis Biotherapeutics, Inc.NASDAQ: ARQT
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income turns positive
Q2 FY2026 net income was $15.01M, compared with -$15.89M a year earlier. Trailing-twelve-month net income was $28.52M. Over 3 fiscal years it compounded at -62.7% a year.
Context
- Net income amounted to 4.3% of revenue in FY2025, down 67.0 pp from a year earlier.
- Net income grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of $43.52M (+369.6%) for the fiscal year ending Dec 2026, a step up from the -88.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $15.01M+232.9% QoQ
- Last fiscal yearDec 2025
- -$16.14M-88.5% YoY
- LTMJun 2026
- $28.52M+130.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +194.5% | +232.4% | +37.9 pp |
| 1 year | -88.5% | +369.6% | +458.1 pp |
| 3-year CAGR | -62.7% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (16.14M) USD
- Year-over-year change
- +88.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (16.14M) | +88.5% |
| FY2024 | 2024-12-31 | (140.04M) | +46.6% |
| FY2023 | 2023-12-31 | (262.14M) | +15.8% |
| FY2022 | 2022-12-31 | (311.46M) | -50.9% |
| FY2021 | 2021-12-31 | (206.36M) | — |
Net Income vs competitors
How ARQT compares with its peers on the latest reported figures
- ARQT's LTM Jun 2026 net income of $28.52M is the 3rd largest of the 6 companies compared; the peer median is $27.37M.
- Its year-over-year change of +130.6% is the highest of 3, against a peer median of -49.5%.
- Net income amounts to 6.1% of revenue for ARQT, versus a peer median of 759.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
EVMNEvommune, Inc. | LTM Mar 2026 | $75.99M | — | — | 759.9% |
| LTM Mar 2026 | $69.66M | -46.5% | -9.3% | 832.6% | |
| LTM Jun 2026 | $28.52M | +130.6% | -62.7% | 6.1% | |
| LTM Mar 2026 | $27.37M | -52.6% | -18.3% | — | |
| LTM Jun 2024 | $14.92M | — | -25.7% | 227.4% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $3.84M | — | — | — |
| Peer median (excluding ARQT) | $27.37M | -49.5% | -18.3% | 759.9% | |
Competitors are the stored peer set for ARQT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (206.36M) | (311.46M) | (262.14M) | (140.04M) | (16.14M) |
| Depreciation & Amortization | 454K | 934K | 750K | 2.6M | 4.67M |
| Deferred Income Tax | 3.45M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 23.89M | 32.68M | 38.81M | 41.73M | 40.36M |
| Change in Working Capital | 3.62M | (10.18M) | (23.5M) | (15.08M) | (34.83M) |
| Accounts Receivables | 0 | (8.46M) | (17.35M) | (47.26M) | (73.16M) |
| Inventory | 0 | (7.51M) | (5.62M) | (400K) | (7.33M) |
| Accounts Payables | 245K | 1.57M | 3.15M | 2.23M | (1.69M) |
| Other Working Capital | 3.38M | 4.23M | (3.68M) | 30.35M | 47.36M |
| Other Non-Cash Items | 309K | 30.3M | (979K) | (1.37M) | 314K |
| Operating Cash Flow | (174.63M) | (257.72M) | (247.06M) | (112.16M) | (5.63M) |
| Capital Expenditures | (995K) | (23.28M) | (428K) | (143K) | (686K) |
| Acquisitions (Net) | 74.96M | 22.95M | 0 | 0 | 0 |
| Purchases of Investments | (292.51M) | (415.39M) | (225.84M) | (254.82M) | (246.99M) |
| Sales of Investments | 217.55M | 351.47M | 406.5M | 288.78M | 227.42M |
| Other Investing Activities | (74.96M) | (22.95M) | 0 | (5M) | (10M) |
| Investing Cash Flow | (75.95M) | (87.2M) | 180.23M | 28.82M | (30.25M) |
| Debt Repayment | 73.99M | 125M | 0 | (100M) | 0 |
| Common Stock Issued | 207.49M | 176.05M | 98.9M | 161.68M | 6.97M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 470K | 751K | 2.42M | 4.52M | 0 |
| Financing Cash Flow | 281.95M | 301.8M | 101.32M | 66.2M | 6.97M |
| Effect of Forex Changes | 0 | 0 | (50K) | (235K) | 168K |
| Net Change in Cash | 31.37M | (43.12M) | 34.45M | (17.37M) | (28.74M) |
| Free Cash Flow | (175.62M) | (281M) | (247.49M) | (112.3M) | (6.31M) |
Arcutis Biotherapeutics, Inc.
NASDAQ:ARQT
Intrinsic Alpha fair value
Locked
Current Price
$27.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.